Signature Diagnostics AG Appoints Rainer Kramer to Chief Business Officer and Member of the Management Board
Published: Sep 30, 2010
POTSDAM, GERMANY--(Marketwire - September 30, 2010) - Signature Diagnostics / Signature Diagnostics Appoints Rainer Kramer to Chief Business Officer and Member of the Management Board processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Potsdam, Germany, September 30, 2010 - Signature Diagnostics AG announced today the appointment of Rainer Kramer as Chief Business Officer. Dr. Kramer previously held the position of Vice President Corporate Business Development at Jerini AG, where he was responsible for all licensing, partnering, and alliance management activities. Before joining Jerini, he performed various research and business development functions at MorphoSys AG, Martinsried, and Amgen Inc., Thousand Oaks.
"We are delighted to bring Rainer on board to help us exploit the enormous potential of Signature's pioneering and best-in-class products for early detection and prognosis of colorectal cancer," said André Rosenthal, CEO of Signature. "Signature will launch its first products in early 2011 in certain EU markets, either alone or with commercial partners, and Rainer's business savvy and deal-making experience make him ideal to help lead Signature forward in this pivotal next stage."
"I'm very excited to work with Signature's dynamic team to introduce innovative tests that may change the face of detecting colorectal cancer," stated Dr. Kramer. "The potential of these products to significantly improve both the diagnosis and prognosis of one of the most common cancers worldwide is far-reaching. By bringing CRC screening to a new level of accuracy and sensitivity, these tests can detect cancer when it is still curable, thereby improving survival rate."
Dr. Kramer holds a Diploma in Molecular Biology and a Ph.D from the Max-Planck-Institute for Neurobiology. Throughout his career in corporate business development, he contributed or delivered numerous strategic partnerships and license deals encompassing technology platform and product deals as well as equity transactions with an aggregate value of several hundred million Euros. As a member of Jerini's M&A committee, he was instrumental in the sale of Jerini to Shire in 2008 and was Shire's appointed principal for the sale of JPT GmbH in 2009.
About Signature Diagnostics AG
Signature Diagnostics is a molecular oncology diagnostics company based in Potsdam, Germany, focusing on the development and commercialization of innovative and proprietary diagnostic products for the prognosis and early detection/screening of colorectal cancer. Signature Diagnostics sponsors and conducts large prospective, multicenter clinical trials with more than 25 primary care hospitals and several dozen colonoscopy centers in Germany to discover and validate biomarkers for early detection/screening and prognosis of colorectal and other cancers. The company's first products, Predictor C and Detector C, will be launched in early 2011 in its own ISO15189 certified service laboratory. For more information about Signature Diagnostics' colorectal cancer tests, please visit http://www.signature-diagnostics.de/.
--- End of Message ---
Signature Diagnostics Hermannswerder 20 A Potsdam Germany
Press release (PDF): http://hugin.info/143237/R/1448035/390470.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Signature Diagnostics via Thomson Reuters ONE
Prof. Dr. Andre Rosenthal
14473 Potsdam, Germany